These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27777939)

  • 41. Coexistence of Chronic Myelomonocytic Leukemia and Ulcerative Colitis With Rapid Progression to Acute Myelomonocytic Leukemia: A Case Report.
    Pelkey LJ; Graham DM; Zakem MH; Muza-Moons MM
    Cureus; 2022 Feb; 14(2):e22422. PubMed ID: 35228982
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia.
    Binder M; Carr RM; Lasho TL; Finke CM; Mangaonkar AA; Pin CL; Berger KR; Mazzone A; Potluri S; Ordog T; Robertson KD; Marks DL; Fernandez-Zapico ME; Gaspar-Maia A; Patnaik MM
    Nat Commun; 2022 Mar; 13(1):1434. PubMed ID: 35301312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.
    Patnaik MM; Padron E; LaBorde RR; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Al-kali A; Pardanani A; Ali NA; Komrokji RS; Tefferi A
    Leukemia; 2013 Jul; 27(7):1504-10. PubMed ID: 23531518
    [TBL] [Abstract][Full Text] [Related]  

  • 44. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
    Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
    Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation.
    Peng J; Zuo Z; Fu B; Oki Y; Tang G; Goswami M; Priyanka P; Muzzafar T; Medeiros LJ; Luthra R; Wang SA
    Eur J Haematol; 2016 Jan; 96(1):65-71. PubMed ID: 25809997
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene mutation profile and risk stratification in AML1‑ETO‑positive acute myeloid leukemia based on next‑generation sequencing.
    Yu G; Yin C; Wu F; Jiang L; Zheng Z; Xu D; Zhou J; Jiang X; Liu Q; Meng F
    Oncol Rep; 2019 Dec; 42(6):2333-2344. PubMed ID: 31638252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Role of ASXL1 mutation in myeloid malignancies].
    Sheng MY; Zhou Y; Xu MJ; Yang FC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chronic myelomonocytic leukemia as a transformation from polycythemia vera.
    Andrei M; Pandey A; Avezbakiyev B; Wang JC
    Leuk Res Rep; 2019; 11():14-16. PubMed ID: 30949429
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
    Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
    Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current management of patients with chronic myelomonocytic leukemia.
    Alfonso A; Montalban-Bravo G; Garcia-Manero G
    Curr Opin Oncol; 2017 Jan; 29(1):79-87. PubMed ID: 27849645
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing.
    Patnaik MM; Lasho TL; Finke CM; Hanson CA; King RL; Ketterling RP; Gangat N; Tefferi A
    Am J Hematol; 2016 May; 91(5):492-8. PubMed ID: 26874914
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review.
    Patnaik MM; Parikh SA; Hanson CA; Tefferi A
    Br J Haematol; 2014 May; 165(3):273-86. PubMed ID: 24467717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.
    Patnaik MM; Wassie EA; Padron E; Onida F; Itzykson R; Lasho TL; Kosmider O; Finke CM; Hanson CA; Ketterling RP; Komrokji R; Tefferi A; Solary E
    Blood Cancer J; 2015 Jan; 5(1):e270. PubMed ID: 25555161
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
    Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
    Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of mutations in epigenetic modifiers in acute myeloid leukemia: A systematic review and meta-analysis.
    Al-Bulushi F; Al-Riyami R; Al-Housni Z; Al-Abri B; Al-Khabori M
    Front Oncol; 2022; 12():967657. PubMed ID: 36518313
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes.
    Castaño-Díez S; López-Guerra M; Bosch-Castañeda C; Bataller A; Charry P; Esteban D; Guijarro F; Jiménez-Vicente C; Castillo-Girón C; Cortes A; Martínez-Roca A; Triguero A; Álamo JR; Beà S; Costa D; Colomer D; Rozman M; Esteve J; Díaz-Beyá M
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.
    Schnittger S; Eder C; Jeromin S; Alpermann T; Fasan A; Grossmann V; Kohlmann A; Illig T; Klopp N; Wichmann HE; Kreuzer KA; Schmid C; Staib P; Peceny R; Schmitz N; Kern W; Haferlach C; Haferlach T
    Leukemia; 2013 Jan; 27(1):82-91. PubMed ID: 23018865
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].
    Harada Y; Harada H
    Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
    Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
    J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation by Flow Cytometry of Mature Monocyte Subpopulations for the Diagnosis and Follow-Up of Chronic Myelomonocytic Leukemia.
    Picot T; Aanei CM; Flandrin Gresta P; Noyel P; Tondeur S; Tavernier Tardy E; Guyotat D; Campos Catafal L
    Front Oncol; 2018; 8():109. PubMed ID: 29707521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.